CliffBio
small molecule

TEFLARO

CEFTAROLINE FOSAMIL

Loss of exclusivityFebruary 2031latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameTEFLARO
Active ingredientCEFTAROLINE FOSAMIL
Strength600MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2010
Marketing statusRX

Listed patents

PatentExpiresType
8247400February 2031product
9629861September 2030product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TEFLARO patent cliff — loss of exclusivity February 2031 | CliffBio